Cochlear Implants
by Cochlear Guest Author

2021 Annual Reliability Report

July 25, 2022
Share

Cochlear is proud to share our 2021 Annual Reliability Report.


With more than three decades of reporting on reliability, our commitment to you and your patients remains constant as we continue with our history of transparent reporting in compliance with the European Consensus statement and ANSI/AAMI standards.

Coming off of 2022 American Cochlear Implant Alliance conference in Washington DC, specific scientific sessions were centered on reliability and the clinical impacts of reimplantation. Panel discussions focused on clinic experience with recent revision surgeries including development of revision assessment protocols, electrode selection, changes in electrode placement and speech perception outcomes. While it is important to understand the clinical experience and impact to patients, it most important to minimize the incidence of reimplantation through quality and reliable implants.


Cochlear™ Nucleus® Implants continue to demonstrate industry leading reliability over decades – not just the first few years. Our CI22M Implants, first introduced in 1985, have set the industry benchmark and show a greater than 90% cumulative survival rate as we approach 35 years since the first implants. We continued our commitment to quality with the CI24M implants, first introduced in 1997, that show 96.0% cumulative survival rate within 25 years. Our focus on long-term reliability is allowing our recipients implanted more than 30 years ago to engage in the world around them in ways they did not imagine; taking advantage of the latest smart sound processing technology, engaging with others through wireless streaming with their compatible* devices and taking advantage of remote care.


The hearing a cochlear implant provides is life-changing for both your patients and their family and friends. Your patients look to you for guidance when it comes to the facts about short- and long-term reliability. For all the latest information please take time to review our reports and understand the differences between manufacturers because without long-term reliability, everything else is a compromise.

Sincerely,
Lisa Aubert
President, Cochlear Americas

Read the 2021 Annual Reliability Report here!

For complete smartphone compatibility information, please visit www.cochlear.com/compatibility

  1. Cochlear Limited. D1932780 V1 2021-03. Cochlear Nucleus System Reliability Report Volume 20, December 2021.
Author

Cochlear Guest Author

In an effort to keep our content fresh and reflective of a diverse industry, Cochlear Americas features a mix of employees and professional partners to contribute to Cochlear ProNews as Guest Authors.

View all posts

Related Posts

Clinical Recommendations for Effective Electric-Acoustic Stimulation Treatment for Patients with Severe High-Frequency Hearing Loss

October 5, 2023

Clinical White Paper

In October 2022, Cochlear’s Clinical Team hosted a customer workshop, “Considerations for Effective Treatment of Severe High-Frequency Sensorineural Hearing Loss.” This meeting brought together 27 Key Opinion Leaders (14 surgeons and 13 audiologists) from across the United States and was moderated by Dr. Bruce Gantz and Dr. Camille Dunn from the University of Iowa and Dr. René Gifford from Vanderbilt University. The purpose of the workshop was to discuss and gather group agreement on key areas of Electric-acoustic Stimulation (EAS) clinical care including candidacy, definition of hearing preservation functional vs. measurable, programming guidelines, and product enhancements.

The Clinical Team is pleased to share with you a White Paper below summarizing the benefits of EAS technology and the EAS clinical care recommendations based on the outcomes of the Thought Leader Workshop. Here is a sneak peak of what can be found in the White Paper.

What are the benefits of EAS over electric-only?

What terminology is used when describing different device configurations?

Who are EAS candidates?

What other EAS care recommendations can be found in the White Paper?

  • Surgical recommendations
  • Programming recommendations
  • Postoperative evaluation care model
  • Reporting results

Click here to access the full White Paper.

FUN5083-ISS1-MAY23-EAS-White-Paper-1Download

The benefits of upgrading to new technology

November 5, 2020

By Allison Biever, AuD, Rocky Mountain Ear Center

Why upgrade to newer technology? Dr. Biever shares her experience working with cochlear implant recipients to maximize hearing outcomes.

Next to the joy of sharing a recipient’s first moments of hearing with their cochlear implant is the wonder of watching a recipient experience upgraded technology as they frequently exhibit emotions of gratitude, disbelief, giddiness and utter delight.

Upgraded technology helps provide recipients with better hearing and new freedoms. When recipients get upgraded to technology that allows them to stream music and phone calls wirelessly, I often hear, “You mean you can’t hear what I am hearing?”  Bilateral recipients have often had to use speaker phone on their cell phones to enjoy a call or listen to music with both ears. The expectation is that everyone is privy to their phone calls and hearing their music.

Moreover, patients tend to report that sound quality is also better when streaming phone calls, and it’s easier to understand the caller and look more relaxed talking to the caller. One of my adult recipients reported that after getting upgraded to new processors, he decided to create his first playlist because for the first time in his life – music sounded so good!

Upgraded technology can demonstrate additional benefits with regard to wearability. For example, some of my recipients are excited to now make it through the day on a single battery charge. Patients have also reported benefits due to the improved size and weight of the processor. Previously, playing sports, dancing or even doing yoga could be difficult because the size and weight of the processors prevented the processor from sitting securely on their ear. 

One unexpected benefit of upgraded technology is that recipients may now make important processor adjustments which can improve their hearing ability or comfort with sound. Historically, if recipients needed significantly more volume or less treble for example, they needed to come back to the implant program so adjustments could be made.  With current upgraded technology and use of the Nucleus® Smart App, patients can have increased volume capabilities.

From an audiologist’s perspective, it has been amazing to see the improvements in technology that have taken place over the past 20 years. The future looks bright and undoubtedly, sounds better than ever!

To learn more about upgraded technology, visit our website!

This article expresses the experience and opinions of Allison Biever.

The Cochlear Nucleus 7 Sound Processor is compatible with iPhone, iPad and iPod touch. Apple, the Apple logo, FaceTime, Made for iPad logo, Made for iPhone logo, Made for iPod logo, iPhone, iPad Pro, iPad Air, iPad mini, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. The Cochlear Nucleus Smart App is available on App Store and Google Play. For complete smartphone compatibility information, please visit www.cochlear.com/compatibility.

Cochlear logo - white

©Cochlear Limited 2024. All rights reserved. ACE, Advance Off-Stylet, AOS, Ardium, AutoNRT, Autosensitivity, Baha, Baha SoftWear, BCDrive, Beam, Bring Back the Beat, Button, Carina, Cochlear, 科利耳, コクレア, 코클리어, Cochlear SoftWear, Contour, コントゥア, Contour Advance, Custom Sound, DermaLock, Freedom, Hear now. And always, Hugfit, Human Design, Hybrid, Invisible Hearing, Kanso, LowPro, MET, MP3000, myCochlear, mySmartSound, NRT, Nucleus, Osia, Outcome Focused Fitting, Off-Stylet, Piezo Power, Profile, Slimline, SmartSound, Softip, SoundArc, True Wireless, the elliptical logo, Vistafix, Whisper, WindShield and Xidium are either trademarks or registered trademarks of the Cochlear group of companies. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

 

This material is intended for health professionals. If you are a consumer, please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always read the instructions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

 

Cochlear ProNews is monitored Monday through Friday, excluding some holidays. Questions and inquiries submitted over the weekends or holidays may see a delay in response. For immediate assistance please contact us directly. You are solely responsible for your interactions with other members of our Websites. Cochlear reserves the right, but has no obligation, to monitor disputes or communications between you and other members of our Websites. For a full list of Cochlear’s terms of use, click here.